Description
This Kalorama Information report, The Worldwide Market for Prescription Dermatological Drugs represents the eighth time that Kalorama has detailed the various categories of prescription dermatological drugs, describing the global market and identifying major market factors that may help to shape the market for treatments in the future. It is a time of change for this market sector, with OTC product launches, rising skin cancer incidence and acquisitions in the industry, and this report takes those updated details into account in its comprehensive analysis.
Full Coverage of Key Prescription Dermatological Drug SegmentsThe global market for prescription dermatology drugs includes products in the following categories:
- Prescription Acne and Rosacea Drugs
-
(Benzoyl, Retinoids, Antibiotics, Other)
- Prescription Antiaging and Photodamage Drugs
-
(Keratolytics, Moisturizers, Retinoids, Sun-screens, Other Agents)
- Prescription Dermatitis and Seborrhea Drugs
-
(Topical, Systemic, Others)
- Prescription Fungal Infection Drugs
- Prescription Hair Loss and Hair Removal Drugs
-
(Antiandrogens, Androgen Inhibitors, Others)
- Prescription Hyperpigmentation/Melasma Drugs
-
(Hyperpigmentation/Melasma Agents, Depigmenting Agents)
- Prescription Psoriasis Drugs
-
(Topical, Systemic, Other)
- Prescription Skin Cancer Drugs
- Other Prescription Skin Disorder Drugs
(Antiviral Drugs, Antiparasitic Agents)
Cosmetic Medications Get PreferenceA poor pipeline of new products has hurt pharmaceutical companies broadly. Reliance on blockbuster drugs is a longshot strategy and major companies are shifting focus to cosmetic medications. By doing this, many manufacturers are realizing less scrutiny from the FDA and a growing need in the niche markets such as dermatology.
This transition will play a role in the future development of the dermatological industry over the forecast period. The global pharmaceutical sector has little choice but to continue expanding through mergers and acquisitions for some time to come.
A Look at Key Trends in DermatologicsIt’s a very dynamic time for the prescription dermatological drug industry. Consolidation, economic times, new technologies and genetic discoveries are among the trends that the industry is seeing. The following are among the trends analyzed in this report:
- Shift in Growth Areas: Since the last edition, some parts of the market experienced growth and others less so. Market watchers will want to stay informed with what innovators are focusing on.
- Slow Economic Recovery: The prescription dermatological drug industry was not immune to the recent economic downturn and weak recovery Some product categories fared better than others, and these areas are detailed in the report.
- Medi-Spas: Increasing trend to provide convenience and pampering for customers through the offering of the Medi-Spa. Medi-spas utilize lasers and intense pulsed light technology as well as medical microdermabrasion, photofacials, Botox and Restylane injections, medical peels and other medical beauty procedures.
-
- Healthcare Reform: In March 2010, the US government enacted the Patient Protection and Affordable Care Act (PPACA). The PPACA includes provisions that have a significant negative impact on sales in many of the dermatology product categories, including an extension of Medicaid and Medicare benefits to new patient populations, an increase in Medicaid rebates owed by manufacturers under the Medicaid Drug Rebate Program and a future increase in the initial coverage limit for Medicare patients.
-
- The “Gray Areas of Medicine”: Treating the whole person is recognized in today’s medicine as an important adjunct of the traditional examination, diagnosis, treatment and recovery, which leads to the role of dermatologists, plastic surgeons and other medical players in this market.
-
- Cosmetic Dermatologists: The report discusses the debate over a new function for dermatologists in cosmetic procedures.
-
- Patient Compliance: Drugs are only effective if patients comply with dosage and time of administration. This is an increasing concern for dermatologists and the industry.
-
- Melanoma Survival Rates Falter: While some other cancers have declined in incidence, melanoma remains a growing problem, and new dermatological aids will be in demand.
-
- Phosphatidylglycerol and Psoriasis: Researchers now understand more about this lipid and how it may affect psoriasis.
-
- Aesthetic Medicine: Popularity of aesthetic treatments are driving drug sales.
-
- New Filler Options: Collagen has been used for twenty years; now two new filler products are being developed and more could be on the way.
-
- Consumer Confusion: This is a highly competitive market. With information overload on product choices, its up to the industry to educate.
-
- Genetic Link to Psoriasis: Discovery of a possible block to the pathway that activates T cells could change treatment.
- Rx-to-OTC Switches: Several dermatological products that were prescription are now available OTC.
-
- Cosmeceuticals: New personal care products, incorporating antioxidants and polypeptides, that go beyond topical moisturizers and anti-wrinkle creams will be a factor in this market.
-
- Teledermatology: The taking of and sending of digital pictures for consultation has changed medical practice in this specialty.
- Reimbursement Issues: The coverage of dermatological drugs can be very limited.
-
- Photodynamic Therapy: A possible replacement for surgical excision of primary skin cancer.
- Synthetic Lipids for Skin Healing: Pseudoceramides that are involved in skin cell growth could be used in treating skin diseases in which skin cells grow abnormally.
- Importance of Drug Delivery: Microdermabrasion and novel electrophoretic products are among the delivery systems that could be seen in future products.
-
The information and analysis presented in this report are based on extensive interviews with senior management of top companies in the dermatology market. Background information was obtained from a comprehensive search of published literature and reports obtained from various government, business, medical trade, and international journals. Key information from published literature was used to conduct interviews with over 42 industry executives and product managers to validate and obtain expert opinion on current and future trends in the dermatological market. Interviews were also used to confirm and/or adjust market size estimates, as well as in formulating market projections.
The following companies are profiled in this report:
- Allergan Inc.
- Allergan Inamed Corporation
- Barrier Therapeutics, Inc
- Bayer AG
- PharmaDerm Pharmaceuticals, Inc
- Bristol-Myers Squibb
- Collagenex (now Galderma) Pharmaceuticals
- Galderma S.A.
- Genentech, Inc.
- GlaxoSmithKline Plc
- Johnson & Johnson (Janssen Pharmaceutica, Ortho
Dermatological, Ortho-McNeil)
- Medicis Pharmaceutical Corporation
- Merck & Company, Inc.
- Mylan Pharmaceuticals, Inc,
- Novartis Pharmaceuticals Corporation
- Nycomed Inc.
- Pfizer, Inc.
- Q-Med AB
- Roche Group (F. Hoffmann-La Roche Ltd.)
- Schering (now Merck)-Plough Corporation
- Sinclair Pharma Plc.
- SkinMedica
- Stiefel Laboratories, Inc.
- Valeant Pharmaceuticals, Inc.
All market data pertains to the global market at the manufacturers’ level. Data are expressed in current U.S. dollars. The base year for data was 2011. Historical data are provided for each of the years 2009 to 2010, and forecast data are provided for each of the years 2011 through 2016. Historical, base year, and forecast data are provided for each market segment. Market shares are provided for each market segment for the 2011 base year.
Table of Contents
CHAPTER ONE: EXECUTIVE SUMMARY
- Introduction
- Scope and Methodology
- Size and Growth of the Market
- Issues and Trends Affecting Market
- Competitor Analysis
CHAPTER TWO: INTRODUCTION
- Structure and Function of the Skin
- Epidermis
- Dermis
- Subcutaneous Tissue
- Epidermal Appendages
- Functions of the Skin
- Effects of Aging on the Skin
- Dermatological Conditions and Treatment
- Pharmacokinetics
- Drug Absorption
- Distribution
- Bioavailability
- Drug Delivery Methods
- Demographics of Skin Disorders, Incidence, and Prevalence
CHAPTER THREE: ISSUES AND TRENDS
- Patient ComplianceCosmetic Dermatologists
- Melanoma Survival Rates Falter
- Phosphatidylglycerol and Psoriasis
- New Itch Gene Found
- New Filler Options
- Consumer Confusion
- Genetic Link to Psoriasis
- Biologic Dermatology
- Rx-to-OTC Switches
- Cosmeceuticals
- Antioxidants
- Polypeptides
- Teledermatology
- Reimbursement Issues
- Accutane IPledge Program
- Laser Therapy
- Narrowband Ultraviolet B
- Photodynamic Therapy
- New Oral Medications and Research for Acne
- Synthetic Lipids for Skin Healing
- Importance of Drug Delivery
CHAPTER FOUR: PRESCRIPTION ANTIACNE AND ROSACEA DRUGS
- Description of DisordersDescription of Products
- Benzoyl Peroxide
- Description of Products
- Current Suppliers
- Retinoids
- Topical Formulations
- Systemic Formulations
- Current Suppliers
- Antibiotics
- Description of Products
- Current Suppliers
- Oral Contraceptives
- Research and Development
- Market Size and Growth
- Global Market
- Markets by Geographical Region
- United States
- Europe
- Japan
- Rest of World
- The Future of the Market
- Competitive Analysis
CHAPTER FIVE: PRESCRIPTION ANTIAGING AND PHOTODAMAGE DRUGS
- OverviewDescription of Products
- Keratolytics
- Moisturizers
- Retinoids
- Sunscreens
- Other Agents
- Research and Development
- Market Size and Growth
- Global Market
- Markets by Geographical Region
- United States
- Europe
- Japan
- Rest of World
- The Future of the Market
- Competitive Analysis
CHAPTER SIX: PRESCRIPTION DERMATITIS AND SEBORRHEA DRUGS
- OverviewDescription of Products
- Topical Corticosteroids
- Systemic Corticosteroids
- Other Products
- Research and Development
- Market Size and Growth
- Global Market by Type
- Markets by Geographical Region
- United States
- Europe
- Japan
- Rest of World
- Future of the Market
- Competitive Analysis
CHAPTER SEVEN: PRESCRIPTION ANTIFUNGAL DRUGS
- OverviewDescription of Products
- Systemic Formulations
- Terbinafine
- Itraconazole
- Fluconazole
- Griseofulvin
- Ketoconazole
- Current Suppliers
- Topical Formulations
- Polyenes
- Azoles
- Allylamines and Benzylamines
- Other Topical Formulations
- New Products
- Current Suppliers
- Research and Development
- Market Size and Growth
- Global Market by Type
- Markets by Geographical Region
- United States
- Europe
- Japan
- Rest of World
- Future of the Market
- Competitive Analysis
CHAPTER EIGHT: PRESCRIPTION HAIR LOSS AND HAIR REMOVAL DRUGS
- OverviewDescription of Products
- Antiandrogens
- Androgen Inhibitors
- Oral Contraceptives
- Other Treatments
- Research and Development
- Market Size and Growth
- \ Global Market by Type
- Markets by Geographical Region
- United States
- Europe
- Japan
- Rest of World
- Future of the Market
- Competitive Analysis
CHAPTER NINE: PRESCRIPTION HYPERPIGMENTATION / MELASMA DRUGS
- OverviewDescription of Products
- Research and Development
- Market Size and Growth
- Global Market
- Markets by Geographical Region
- United States
- Europe
- Japan
- Rest of World
- The Future of the Market
- Competitive Analysis
CHAPTER TEN: PRESCRIPTION PSORIASIS DRUGS
- OverviewDescription of Products
- Topical Psoriasis Products
- Anthralin
- Coal Tar
- Methoxsalen
- Second-generation Retinoids
- Tazarotene
- Topical Vitamin D
- Vitamin D Analogs
- Vanos
- Systemic Psoriasis Preparations
- Betamethasone
- Cortisone Acetate
- Cyclosporine
- Hydrocortisone
- Methotrexate
- Olopatadine Hydrochloride
- Tacrolimus
- Light Therapy
- Biologics
- Research and Development
- Market Size and Growth
- Global Market by Type
- Markets by Geographical Region
- United States
- Europe
- Japan
- Rest of World
- Future of the Market
- Competitive Analysis
CHAPTER ELEVEN: PRESCRIPTION SKIN CANCER DRUGS
- Overview
- Nonmelanoma Skin Cancers
- Actinic Keratoses
- Basal Cell Carcinoma
- Squamous Cell Carcinoma
- Cutaneous T-cell Lymphoma
- Dysplastic Nevus Syndrome
- Malignant Melanoma
- Description of Products
- 5-Fluorouracil
- Mechlorethamine/Nitrogen Mustard
- Carmustine/BCNU (Topical)
- Vinblastine (Intralesional) and Others
- Research and Development
- Market Size and Growth
- Global Market
- Markets by Geographical Region
- United States
- Europe
- Japan
- Rest of World
- The Future of the Market
- Competitive Analysis
CHAPTER TWELVE: MISCELLANEOUS SKIN DISORDER DRUGS—ANTIVIRALS AND ANTIPARASITICS
- Overview
- Antivirals
- Antiparasitics
- Description of Products
- Topical Antivirals
- Antiviral Drugs
- Immunoenhancing Drugs
- Current Suppliers
- Antiparasitic Agents
- Current Suppliers
- Other Skin Related Products
- Research and Development
- Market Size and Growth
- Global Market
- Markets by Geographical Region
- United States
- Europe
- Japan
- Rest of World
- The Future of the Market
- Competitive Analysis
CHAPTER THIRTEEN: WORLD MARKET SUMMARY
- Overview
- Total Market Size and Forecast
- Market and Competitive Analysis
CHAPTER FOURTEEN: CORPORATE PROFILES
- Allergan Inc.
- Allergan Inamed Corporation
- Barrier Therapeutics, Inc
- Bayer AG
- PharmaDerm Pharmaceuticals, Inc
- Bristol-Myers Squibb
- Collagenex (now Galderma) Pharmaceuticals
- Galderma S.A.
- Genentech, Inc.
- GlaxoSmithKline Plc
- Johnson & Johnson (Janssen Pharmaceutica, Ortho Dermatological, Ortho-McNeil)
- Medicis Pharmaceutical Corporation
- Merck & Company, Inc.
- Mylan Pharmaceuticals, Inc,
- Novartis Pharmaceuticals Corporation
- Nycomed Inc.
- Pfizer, Inc.
- Q-Med AB
- Roche Group (F. Hoffmann-La Roche Ltd.)
- Schering (now Merck)-Plough Corporation
- Sinclair Pharma Plc.
- SkinMedica
- Stiefel Laboratories, Inc.
- Valeant Pharmaceuticals, Inc.
TABLE OF EXHIBITS
CHAPTER ONE: EXECUTIVE SUMMARY
- Table 1-1: The Global Market for Prescription Dermatological Drugs 2001, 2006, and 2011Figure 1-1: The Global Market for Prescription Dermatological Drugs 2001, 2006, and 2011
CHAPTER TWO: INTRODUCTION
Table 2-2: Worldwide Incidence and Prevalence of Selected Dermatologic ConditionsCHAPTER THREE: ISSUES AND TRENDS
Table 3-1: Selected Dermatological Rx-to-OTC SwitchesCHAPTER FOUR: PRESCRIPTION ANTIACNE AND ROSACEA DRUGS
- Table 4-1: Common Benzoyl Peroxide Formulations
- Table 4-2: Common Retinoid Formulations
- Table 4-3: Common Antibiotic Formulations
- Table 4-4: Common Oral Contraceptive Formulations
- Table 4-5: Prescription Acne, Actinic Keratosis and Rosacea Formulations in Development
- Table 4-6: The Global Market for Prescription Acne and Rosacea Drugs by Type 2001-2011
- Figure 4-1: The Global Market for Prescription Acne and Rosacea Drug Revenues by Type, 2001-2011
- Figure 4-2: The Global Market for Prescription Acne and Rosacea Drugs Share by Type 2006
- Figure 4-3: The Global Market for Prescription Acne and Rosacea Drugs Share by Type 2011
- Table 4-7: The Global Market for Prescription Antiacne and Rosacea Drugs by Geographical Region 2001-2011
- Figure 4-4: The Global Market for Prescription Antiacne and Rosacea Drugs Revenues by Geographical Region 2001-2011
- Figure 4-5: The Global Market for Prescription Antiacne and Rosacea Drugs Share by Geographical Region 2006
- Figure 4-6: The Global Market for Prescription Antiacne and Rosacea Drugs Share by Geographical Region 2011
- Table 4-8: Global Market for Prescription Antiacne and Rosacea Drugs Revenues and Market Share by Supplier 2006
- Figure 4-7: Global Market for Acne and Rosacea Drugs Market Share by Leading Supplier 2006
CHAPTER FIVE: PRESCRIPTION ANTIAGING AND PHOTODAMAGE DRUGS
- Table 5-1: Common Prescription Keratolytic Formulations
- Table 5-2: Occlusive Moisturizers—Categories of Ingredients
- Table 5-3: Common Prescription Moisturizers
- Table 5-4: Common Prescription Retinoids for Antiaging and Photodamage
- Table 5-5: Common Prescription Sunscreens
- Table 5-6: Other Prescription Antiaging and Photodamage Products
- Table 5-7: Prescription Antiaging and Photodamage Formulations in Development
- Table 5-8: The Global Market Antiaging and Photodamage Drugs by Type 2001-2011
- Figure 5-1: The Global Market for Antiaging and Photodamage Drugs Revenues by Type 2001-2011
- Figure 5-2: The Global Market for Antiaging and Photodamage Drugs Share by Type 2006
- Figure 5-3: The Global Market for Antiaging and Photodamage Drugs Share by Type 2011
- Table 5-9: The Global Market for Prescription Antiaging and Photodamage |Drugs by Geographical Region 2001-2011
- Figure 5-4: The Global Market for Prescription Antiaging and Photodamage Drugs, Revenues by Geographical Region 2001-2011
- Figure 5-5: The Global Market for Antiaging and Photodamage Drugs Share by Geographical Region 2006
- Figure 5-6: The Global Market for Antiaging and Photodamage Drugs Share by Geographical Region 2011
- Table 5-10: Global Market for Prescription Antiaging and Photodamage Drugs Revenues and Market Share by Supplier 2006
- Figure 5-7: Global Market for Prescription Antiaging and Photodamage Drugs, Market Share by Leading Supplier 2006
CHAPTER SIX: PRESCRIPTION DERMATITIS AND SEBORRHEA DRUGS
- Table 6-1: Common Prescription Topical Corticosteroid Preparations
- Table 6-2 Common Prescription Systemic Corticosteroids
- Table 6-3: Prescription Other Dermatitis Formulations
- Table 6-4: Prescription Dermatitis Formulations in Development
- Table 6-5: The Global Market for Prescription Dermatitis and Seborrhea Drugs by Type 2001-2011
- Figure 6-1: The Global Market for Prescription Dermatitis and Seborrhea Drugs Revenues by Type 2001-2011
- Figure 6-2: The Global Market for Prescription Dermatitis and Seborrhea Drugs Share by Type 2006
- Figure 6-3: The Global Market for Prescription Dermatitis and Seborrhea Drugs Share by Type 2011
- Table 6-6: The Global Market for Prescription Dermatitis and Seborrhea Drugs by Geographical Region 2001-2011
- Figure 6-4: The Global Market for Prescription Dermatitis and Seborrhea Drugs Revenues by Geographical Region 2001-2011
- Figure 6-5: The Global Market for Prescription Dermatitis and Seborrhea Drugs Share by Geographical Region 2006
- Figure 6-6: The Global Market for Prescription Dermatitis and Seborrhea Drugs Share by Geographical Region 2011
- Table 6-7: Global Market for Prescription Dermatitis and Seborrhea Drugs Revenues and Market Share by Supplier 2006
- Figure 6-7: Global Market for Prescription Dermatitis and Seborrhea Drugs Market Share by Leading Supplier 2006
CHAPTER SEVEN: PRESCRIPTION ANTIFUNGAL DRUGS
- Table 7-1: Common Prescription Systemic Antifungal Dermatological Formulations
- Table 7-2: Common Prescription Topical Antifungal Dermatological Drugs
- Table 7-3: Prescription Antifungal Dermatological Drugs in Development
- Table 7-4: The Global Market for Prescription Antifungal Dermatological Drugs by Type 2001-2011
- Figure 7-1: The Global Market for Prescription Antifungal Dermatological Drugs Revenues by Type 2001-2010
- Figure 7-2: The Global Market for Prescription Antifungal Dermatological Drugs Share by Type 2006
- Figure 7-3: The Global Market for Prescription Antifungal Dermatological Drugs, Share by Type 2011
- Table 7-5: The Global Market for Prescription Antifungal Dermatological Drugs by Geographical Region 2001-2011
- Figure 7-4: The Global Market for Prescription Antifungal Dermatological Drugs Revenues by Geographical Region 2001-2011
- Figure 7-5: The Global Market for Prescription Antifungal Dermatological Drugs, Share by Geographical Region 2006
- Figure 7-6: The Global Market for Prescription Antifungal Dermatological Drugs, Share by Geographical Region 2011
- Table 7-6: Global Market for Prescription Antifungal Dermatological Drugs Revenues and Market Share by Supplier 2006
- Figure 7-7: Global Market for Prescription Antifungal Dermatological Drugs Market Share by Leading Supplier 2006
CHAPTER EIGHT: PRESCRIPTION HAIR LOSS AND HAIR REMOVAL DRUGS
- Table 8-1: Common Prescription Hair Loss or Hair Removal Formulations
- Table 8-2: Prescription Hair Loss or Hair Removal Formulations in Development
- Table 8-3: The Global Market for Prescription Hair Loss and Hair Removal Drugs by Type 2001-2011
- Figure 8-1: The Global Market for Prescription Hair Loss and Hair Removal Drugs Revenues by Type 2001-2011
- Figure 8-2: The Global Market for Prescription Hair Loss and Hair Removal Drugs, Share by Type 2006
- Figure 8-3: The Global Market for Prescription Hair Loss and Hair Removal Drugs, Share by Type 2011
- Table 8-4: The Global Market for Prescription Hair Loss and Hair Removal Drugs Revenues by Geographical Region 2001-2011
- Figure 8-4: The Global Market for Prescription Hair Loss and Hair Removal Drugs Revenues by Geographical Region 2001-2011
- Figure 8-5: The Global Market for Prescription Hair Loss and Hair Removal Drugs Share by Geographical Region 2006
- Figure 8-6: The Global Market for Prescription Hair Loss and Hair Removal Drugs Share by Geographical Region 2011
- Table 8-5: Global Market for Prescription Hair Loss and Hair Removal Drugs Revenues and Market Share by Supplier 2006
- Figure 8-7: Global Market for Prescription Hair Loss and Hair Removal Drugs Market Share by Leading Supplier 2006
CHAPTER NINE: PRESCRIPTION HYPERPIGMENTATION/MELASMA DRUGS
- Table 9-1: Common Prescription Hyperpigmentation/Melasma Formulations
- Table 9-2: Common Prescription Depigmenting Agents
- Table 9-3: The Global Market for Hyperpigmentation/Melasma Drugs by Type 2001-2011
- Figure 9-1: The Global Market for Hyperpigmentation/Melasma Drugs Revenues by Type 2001-2011
- Figure 9-2: The Global Market for Prescription Hyperpigmentation/ Melasma Drugs, Share by Type 2006
- Figure 9-3: The Global Market for Prescription Hyperpigmentation/ Melasma Drugs Share by Type 2011
- Table 9-4: The Global Market for Prescription Hyperpigmentation/ Melasma Drugs by Geographical Region 2001-2011
- Figure 9-4: The Global Market for Prescription Hyperpigmentation/ Melasma Drugs Revenues by Geographical Region 2001-2011
- Figure 9-5: The Global Market for Prescription Hyperpigmentation/ Melasma Drugs, Share by Geographical Region 2006
- Figure 9-6: The Global Market for Prescription Hyperpigmentation/ Melasma Drugs, Share by Geographical Region 2011
CHAPTER TEN: PRESCRIPTION PSORIASIS DRUGS
- Table 10-1: Common Prescription Psoriasis Preparations
- Table 10-2: Prescription Psoriasis Preparations in Development
- Table 10-3: The Global Market for Prescription Psoriasis Drugs by Type 2001-2011
- Figure 10-1: The Global Market for Prescription Psoriasis Drugs Revenues by Type 2001-2011
- Figure 10-2: The Global Market for Prescription Psoriasis Drugs Share by Type 2006
- Figure 10-3: The Global Market for Prescription Psoriasis Drugs Share by Type 2011
- Table 10-4: The Global Market for Prescription Psoriasis Drugs by Geographical Region 2001-2011
- Figure 10-4:The Global Market for Prescription Psoriasis Drugs Revenues by Geographical Region 2001-2011
- Figure 10-5: The Global Market for Prescription Psoriasis Drugs Share by Geographical Region 2006
- Figure 10-6: The Global Market for Prescription Psoriasis Drugs Share by Geographical Region 2011
- Table 10-5: Global Market for Prescription Psoriasis Drugs Revenues and Market Share by Supplier 2006
- Figure 10-7: Global Market for Prescription Psoriasis Drugs Market Share by Leading Supplier 2006
CHAPTER ELEVEN: PRESCRIPTION SKIN CANCER DRUGS
- Table 11-1: Malignant Conditions of the Skin
- Table 11-2: Common Prescription Topical and Intralesional Chemotherapeutic Agents
- Table 11-3: Prescription Skin Cancer Preparations in Development
- Table 11-4: The Global Market for Skin Cancer Drugs 2001-2011
- Figure 11-1: The Global Market for Skin Cancer Drugs 2001-2011
- Table 11-5: The Global Market for Prescription Skin Cancer Drugs by Geographical Region 2001-2011
- Figure 11-2: The Global Market for Prescription Skin Cancer Drugs Revenues by Geographical Region 2001-2011
- Figure 11-3: The Global Market for Prescription Skin Cancer Drugs Share by Geographical Region 2006
- Figure 11-4: The Global Market for Prescription Skin Cancer Drugs Share by Geographical Region 2011
- Table 11-12: Global Market for Prescription Skin Cancer Drugs Revenues and Market Share by Supplier 2006
- Figure 11-5: Global Market for Skin Cancer Drugs Market Share by Leading Supplier 2006
CHAPTER TWELVE: MISCELLANEOUS SKIN DISORDER DRUGS –ANTIVIRALS AND ANTIPARASITICS
- Table 12-1: Common Prescription Topical Antiviral Formulations
- Table 12-2: Common Prescription Topical Antiparasitic Formulations
- Table 12-3: Prescription Miscellaneous Skin Preparations in Development
- Table 12-4: The Global Market for Prescription Miscellaneous Skin Disorder Drugs by Type 2001-2011
- Figure 12-1: The Global Market for Miscellaneous Skin Disorder Drugs | Revenues by Type 2001-2011
- Figure 12-2: The Global Market for Miscellaneous Skin Disorder Drugs Share by Type 2006
- Figure 12-3: The Global Market for Miscellaneous Skin Disorder Drugs Share by Type 2011
- Table 12-6: The Global Market for Prescription Miscellaneous Drugs by Geographical Region 2001-2011
- Figure 12-4: The Global Market for Prescription Miscellaneous Drugs Revenues by Geographical Region 2001-2011
- Figure 12-5: The Global Market for Prescription Miscellaneous Drugs
- Share by Geographical Region 2006
- Figure 12-6: The Global Market for Prescription Miscellaneous Drugs Share by Geographical Region 2011
CHAPTER THIRTEEN: WORLD MARKET SUMMARY
- Table 13-1: The Global Market for Prescription Dermatological Drugs, Revenues by Segment, 2001-2011
- Figure 13-1: The Global Market for Prescription Dermatological Drugs Revenues by Dermatological Segment 2001-2011
- Figure 13-2: The Global Market for Dermatological Drugs Market Share by Type 2006
- Figure 13-3: The Global Market for Dermatological Drugs Market Share by Type 2011
- Table 13-3: Global Market for Prescription Dermatological Drugs Revenues and Segments of Participation by Leading Market Participants 2006
